INNOCARE PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.35 HKD | +2.10% |
|
+21.87% | -22.35% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 14,626 | 18,696 | 21,794 | 12,432 | 9,708 | - | - |
| Enterprise Value (EV) 1 | 11,830 | 14,035 | 14,349 | 12,432 | 118.4 | -2,212 | -9,713 |
| P/E ratio | -23.6 x | -249 x | -20.1 x | -16.9 x | -12.1 x | -18.3 x | -91 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10,723 x | 17.9 x | 34.8 x | 16.8 x | 11.4 x | 7.46 x | 5.46 x |
| EV / Revenue | 8,673 x | 13.5 x | 22.9 x | 16.8 x | 0.14 x | -1.7 x | -5.46 x |
| EV / EBITDA | -21.6 x | -93.6 x | -20 x | - | -0.18 x | 4.09 x | 26.3 x |
| EV / FCF | -27.9 x | 9,815 x | -17.8 x | - | -0.23 x | 9.98 x | 127 x |
| FCF Yield | -3.58% | 0.01% | -5.61% | - | -444% | 10% | 0.79% |
| Price to Book | 3.54 x | 3.34 x | 2.8 x | - | 1.55 x | 1.56 x | 1.85 x |
| Nbr of stocks (in thousands) | 1,289,165 | 1,499,673 | 1,764,321 | 1,763,130 | 1,760,932 | - | - |
| Reference price 2 | 11.35 | 12.47 | 12.05 | 6.262 | 4.956 | 4.956 | 4.956 |
| Announcement Date | 21-03-26 | 22-03-22 | 23-03-27 | 24-03-28 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.247 | 1.364 | 1,043 | 625.4 | 738.5 | 848.8 | 1,302 | 1,779 |
| EBITDA 1 | - | -547.5 | -150 | -715.8 | - | -656.8 | -541.3 | -369.8 |
| EBIT 1 | - | -559 | -182.5 | -777.3 | -701.5 | -765.8 | -674.3 | -442.5 |
| Operating Margin | - | -40,981.38% | -17.5% | -124.29% | -94.98% | -90.22% | -51.79% | -24.87% |
| Earnings before Tax (EBT) 1 | - | -464.3 | -20.12 | -893.7 | -644.2 | -685.3 | -495.6 | -228.9 |
| Net income 1 | - | -463.8 | -64.54 | -886.6 | -631.3 | -675.3 | -486.8 | -234.1 |
| Net margin | - | -34,002.42% | -6.19% | -141.76% | -85.47% | -79.56% | -37.39% | -13.16% |
| EPS 2 | -9.320 | -0.4800 | -0.0500 | -0.6000 | -0.3700 | -0.4080 | -0.2715 | -0.0544 |
| Free Cash Flow 1 | - | -423.5 | 1.43 | -804.5 | - | -526 | -221.7 | -76.31 |
| FCF margin | - | -31,049.41% | 0.14% | -128.64% | - | -61.97% | -17.03% | -4.29% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-18 | 21-03-26 | 22-03-22 | 23-03-27 | 24-03-28 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.748 | 0.616 | 101.7 | 941.4 | 246 | 195.7 | 183.8 | 379.4 | - | 159.8 | 201.2 | 361 | 181.6 | 202.1 | 383.8 | 208 | 224.8 | 432.8 | 486.4 | 729.6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | -212.2 | - | -354.9 | -397.6 | -232.6 | -379.7 | - | - | - | -366.3 | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | -208.76% | - | -144.28% | -203.24% | -126.57% | -100.06% | - | - | - | -101.48% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | -0.1600 | 0.1100 | -0.3100 | - | - | -0.2900 | -0.2500 | -0.0600 | - | -0.1200 | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 20-08-21 | 21-03-26 | 21-08-27 | 22-03-22 | 22-08-21 | 22-11-13 | 23-03-27 | 23-03-27 | 23-08-29 | 23-11-13 | 24-03-28 | 24-03-28 | - | - | - | - | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 2,796 | 4,660 | 7,445 | - | 9,590 | 11,920 | 19,421 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -424 | 1.43 | -805 | - | -526 | -222 | -76.3 |
| ROE (net income / shareholders' equity) | - | - | -1.14% | -13.4% | - | -10.8% | -9.24% | -8.23% |
| ROA (Net income/ Total Assets) | - | -13% | -1.08% | -10% | - | -7.7% | -4.3% | -5.8% |
| Assets 1 | - | 3,577 | 5,976 | 8,860 | - | 8,770 | 11,320 | 4,035 |
| Book Value Per Share 2 | - | 3.210 | 3.740 | 4.310 | - | 3.210 | 3.180 | 2.680 |
| Cash Flow per Share 2 | - | -0.2200 | 0.0900 | -0.3800 | - | -0.1900 | - | - |
| Capex 1 | - | 251 | 166 | 239 | - | 143 | 187 | 153 |
| Capex / Sales | - | 18,401.39% | 15.88% | 38.21% | - | 16.89% | 14.36% | 8.6% |
| Announcement Date | 20-03-18 | 21-03-26 | 22-03-22 | 23-03-27 | 24-03-28 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.956
CNY
Average target price
8.987
CNY
Spread / Average Target
+81.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.35% | 1.32B | |
| -1.43% | 103B | |
| +8.96% | 101B | |
| +4.40% | 23.07B | |
| -12.15% | 22.23B | |
| -4.36% | 18.05B | |
| -39.98% | 17.18B | |
| -10.04% | 16.94B | |
| +6.79% | 14.07B | |
| +38.61% | 12.35B |
- Stock Market
- Equities
- 9969 Stock
- Financials InnoCare Pharma Limited
